IntraOp announces two new Mobetron orders in China
Singapore, Jul 20, 2009: US-based company, IntraOp Medical, a provider of Intra-Operative Electron-beam Radiation Therapy (IOERT) solutions for the treatment and eradication of cancer, has announced two new orders for its Mobetron system from its Chinese distribution partner, Hui Long New Technology.
www.biospectrumasia.com

Rumor of Life Science IPO in China
Last week, an acronym surfaced in China life science that hasn’t been heard much lately: IPO. Granted, it was only a rumor, and it was for a drug distribution company, not a drug manufacturer or, an even more unlikely event, for a drug discovery enterprise. But still, it was a sign – perhaps only an early sign – that the investment community’s disinterest in China life science may be coming to an end.
http://www.ebdgroup.com/partneringnews/?q=node/209

NeoStem appoints Chinese medical official to its advisory Board
Singapore, Jul 17, 2009: NeoStem, has entered into an advisory consulting agreement with Dr Cai Jianqian of the Shandong Provincial Association of Chinese Medicine, to assist the company with its expansion into China and facilitate collaborations with prestigious hospitals in the China.
www.biospectrumasia.com

Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
Sundia's Chairman and CEO Dr. Xiaochuan Wang and Executive VP Dr. Xiongwei Shi attended the ceremony with representatives from many biopharmaceutical companies. Ms. Liu Zhengyi, Deputy Director of the Pudong District Government was at the ceremony to extend her congratulations. Mr. Ma Yan, Director of Pudong Customs, Mr. Shi Wenyan, Director of Pudong International Airport Customs, and Mr. Liu Xiaolong, Executive VP of Zhangjiang Group Co. signed a Letter of Intention for Customs' Cooperation to Support Development of Zhangjiang Pharma Valley.
http://news.bionews.com.cn

Bain, FountainVest bid for China medical co
Global and Chinese private equity funds including Bain Capital and FountainVest Partners have submitted bids to buy into a Chinese medical device maker backed by Citigroup (C.N), sources said on Tuesday. http://news.bionews.com.cn

China turns out first batch of antiviral drug for A/H1N1 flu
SHANGHAI, June 26 (Xinhua): China's first batch of antiviral drug for influenza A/H1N1, including 256,000 pills, rolled off the production line in Shanghai Friday. The Oseltamivir Phosphate Capsules, manufactured by the Shanghai Pharmaceutical (Group) Co. Ltd., have passed all quality tests required, Wu Jianwen, president of the company, said Friday. http://news.xinhuanet.com/